Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency
Open Access
Abstract
Introduction Atrial fibrillation (AF) is associated with significantly impaired quality-of-life. Iron deficiency (ID) is prevalent in patients with AF. Correction of ID in other patient populations with intravenous iron supplementation has been shown to be a safe, convenient and effective way of improving exercise tolerance, fatigue and quality-of-life. The IRON-AF (Effect of Iron Repletion in Atrial Fibrillation) study is designed to assess the effect of iron repletion with intravenous ferric carboxymaltose in patients with AF and ID. Methods and analysis The IRON-AF study is a double-blind, randomised controlled trial that will recruit at least 84 patients with AF and ID. Patients will be randomised to receive infusions of either ferric carboxymaltose or placebo, given in repletion and then maintenance doses. The study will have follow-up visits at weeks 4, 8 and 12. The primary endpoint is change in peak oxygen uptake from baseline to week 12, as measured by cardiopulmonary exercise testing (CPET) on a cycle ergometer. Secondary endpoints include changes in quality-of-life and AF disease burden scores, blood parameters, other CPET parameters, transthoracic echocardiogram parameters, 6-minute walk test distance, 7-day Holter/Event monitor burden of AF, health resource utilisation and mortality. Ethics and dissemination The study protocol has been approved by the Central Adelaide Local Health Network Human Research Ethics Committee, Australia. The results of this study will be disseminated through publications in peer-reviewed journals and conference presentations. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12620000285954).Keywords
Funding Information
- National Health and Medical Research Council (N/A)
- National Heart Foundation of Australia (N/A)
- Hospital Research Foundation (N/A)
- Vifor Pharma (N/A)
- University of Adelaide (N/A)
This publication has 37 references indexed in Scilit:
- Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial FibrillationJAMA, 2013
- Iron Deficiency is a Key Determinant of Health-Related Quality of Life in Patients with Chronic Heart Failure Regardless of Anaemia StatusEuropean Journal of Heart Failure, 2013
- Factors Associated With the Epidemic of Hospitalizations Due to Atrial FibrillationThe American Journal of Cardiology, 2012
- The Increasing Burden of Atrial Fibrillation Compared With Heart Failure and Myocardial Infarction: A 15-Year Study of All Hospitalizations in AustraliaArchives of internal medicine (1960), 2012
- Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart FailureJournal of Cardiac Failure, 2011
- Disordered Iron Homeostasis in Chronic Heart FailureJACC, 2011
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron DeficiencyJACC, 2008
- Exercise capacity in atrial fibrillation: A substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T)American Heart Journal, 2007
- Quality of Life and Exercise Performance in Patients in Sinus Rhythm Versus Persistent Atrial FibrillationJACC, 2006